Protein kinase C inhibition in the treatment of mania: A double-blind, placebo-controlled trial of tamoxifen

Archives of General Psychiatry

Volumn 65, Issue 3, 2008, Pages 255-263

  Yildiz, Ayşegül ^a,b   Guleryuz, Sebnem ^c   Ankerst, Donna Pauler ^d   Öngür, Dost ^b   Renshaw, Perry F ^b  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b MCLEAN HOSPITAL   (United States)

^c Altin Ordu Hospital   (Turkey)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; LITHIUM CARBONATE; LORAZEPAM; MOOD STABILIZER; NEUROLEPTIC AGENT; PLACEBO; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; TAMOXIFEN CITRATE; TRANQUILIZER; VALPROIC ACID;

ACNE; ADULT; ANOREXIA; ARTICLE; BIPOLAR I DISORDER; BLOOD PRESSURE; BRAIN TISSUE; CLINICAL FEATURE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRY SKIN; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HEADACHE; HOT FLUSH; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MANIA; PATHOPHYSIOLOGY; PSYCHOSIS; PSYCHOSOMATIC DISORDER; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN TOXICITY; SUICIDE ATTEMPT; TABLET; TURKEY (REPUBLIC); URTICARIA; WEIGHT REDUCTION; YOUNG MANIA RATING SCALE;

ADOLESCENT; ADULT; ANTIMANIC AGENTS; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 40349093181     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2007.43     Document Type: Article

References (57)

1. Manji HK, Lenox RH. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol Psychiatry. 1999;46(10):1328-1351.
2. Quiroz JA, Gould TD, Manji HK. Molecular effects of lithium. Mol Interv. 2004;4(5):259-272.
3. Zarate CA, Singh J, Manji HK. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry. 2006;59(11):1006-1020.
4. Friedman E, Wang HY, Levinson D, Connell TA, Singh H. Altered platelet protein kinase C activity in bipolar affective disorder, manic episode. Biol Psychiatry. 1993;33(7):520-525.
5. Wang HY, Markowitz P, Levinson D, Undie AS, Friedman E. Increased membrane associated protein kinase C activity and translocation in blood platelets from bipolar affective disorder patients. J Psychiatr Res. 1999;33(2):171-179.
6. Hahn CG, Umapathy , Wang HY, Koneru R, Levinson DF, Friedman E. Lithium and valproic acid treatments reduce PKC activation and receptor-G protein coupling in platelets of bipolar manic patients. J Psychiatr Res. 2005;39(4):355-363.
7. Wang HY, Friedman E. Enhanced protein kinase C activity and translocation in bipolar affective disorder brains. Biol Psychiatry. 1996;40(7):568-575.
8. Wang H, Friedman E. Increased association of brain protein kinase C activity with the receptor for activated C kinase-1 (RACK1) in bipolar affective disorder. Biol Psychiatry. 2001;50(5):364-370.
9. Wang HY, Friedman E. Lithium inhibition of protein kinase C activation-induced serotonin release. Psychopharmacology (Berl). 1989;99(2):213-218.
10. Manji HK, Etcheberrigaray R, Chen G, Olds JL. Lithium decreases membrane-associated protein kinase C in hippocampus: selectivity for the alpha isozyme. J Neurochem. 1993;61(6):2303-2310.
11. Chen G, Manji HK, Hawver DB, Wright CB, Potter WZ. Chronic sodium valproate selectively decreases protein kinase C and ? in vitro. J Neurochem. 1994;63(6):2361-2364.
12. Einat H, Manji HK. Cellular plasticity cascades: genes to behavior pathways in animal models of bipolar disorder. Biol Psychiatry. 2006;59(12):1160-1171.
13. Steketee JD. Intra-A10 injection of H7 blocks the development of sensitization to cocaine. Neuroreport. 1994;6(1):69-72.
14. Narita M, Aoki T, Ozaki S, Yajima Y, Suzuki T. Involvement of protein kinase Cγ isoform in morphine-induced reinforcing effects. Neuroscience. 2001;103(2):309-314.
15. Birnbaum SG, Yuan PX, Wang M, Vijayraghavan S, Bloom AK, Davis DJ, Gobeske KT, Sweatt JD, Manji HK, Arnsten AFT. Protein kinase C overactivity impairs prefrontal cortical regulation of working memory. Science. 2004;306(5697):882-884.
16. Bebchuk JM, Arfken CL, Dolan-Manji S, Murphy J, Hasanat K, Manji HK. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiatry. 2000;57(1):95-97.
17. Kulkarni J, Garland KA, Scaffidi A, Headey B, Anderson R, de Castella A, Fitzgerald P, Davis SR. A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology. 2006;31(4):543-547.
18. Einat H, Yuan P, Szabo ST, Dogra S, Manji HK. Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology. 2007;55(3-4):123-131.
19. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Patient Edition. New York: Biometrics Research, New York State Psychiatric Institute; 2002.
20. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-435.
21. Spearing MK, Post R, Leverich G, Brandt D, Nolen W. Modification of the Clinical Global Impressions Scale for use in bipolar illness: the CGI-BP. Psychiatry Res. 1997;73(3):159-171.
22. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6(4):278-296.
23. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
24. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
25. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38(4):963-974.
26. Little RJA. Modeling the drop-out mechanism in repeated-measures studies. J Am Stat Assoc. 1995;90(431):1112-1121.
27. Bowden CL. Key treatment studies of lithium in manic-depressive illness: efficacy and side effects. J Clin Psychiatry. 1998;59(Suppl 6):13-19.
28. Chen G, Masana M, Manji HK. Lithium regulates PKC-mediated intracellular crosstalk and gene expression in the CNS in vivo. Bipolar Disord. 2000;2(3, pt 2):217-236.
29. Lenox RH, Watson DG, Patel J, Ellis J. Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res. 1992;570(1-2):333-340.
30. Watson DG, Lenox RH. Chronic lithium-induced down-regulation of MARCKS in immortalized hippocampal cells: potentiation by muscarinic receptor activation. J Neurochem. 1996;67(2):767-777.
31. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A. 1996;93(16):8455-8459.
32. Chen G, Huang LD, Jiang YM, Manji HK. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem. 1999;72(3):1327-1330.
33. Chen G, Yuan PX, Jiang YM, Huang LD, Manji HK. Valproate robustly enhances AP-1 mediated gene expression. Brain Res Mol Brain Res. 1999;64(1):52-58.
34. Jope RS. Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry. 1999;4(2):117-128.
35. 2-terminal kinases in vitro and in the CNS in vivo. J Neurochem. 1999;73(6):2299-2309.
36. Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK. Lithium-induced increase in human brain grey matter [published correction appears in Lancet. 2000;356(9247):2104]. Lancet. 2000;356(9237):1241-1242.
37. Chen G, Zeng WZ, Yuan PX, Huang LD, Jiang YM, Zhao ZH, Manji HK. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem. 1999;72(2):879-882.
38. Payne JL. The role of estrogen in mood disorders in women. Int Rev Psychiatry. 2003;15(3):280-290.
39. Young RC, Moline M, Kleyman F. Hormone replacement therapy and late-life mania. Am J Geriatr Psychiatry. 1997;5(2):179-181.
40. Kumar C, McIvor RJ, Davies T, Brown N, Papadopoulos A, Wieck A, Checkley SA, Campbell IC, Marks MN. Estrogen administration does not reduce rate of recurrence of affective psychosis after childbirth. J Clin Psychiatry. 2003;64(2):112-118.
41. Zarate CA, Manji HK. Efficacy of a PKC inhibitor (tamoxifen) in the treatment of acute mania: double-blind, placebo-controlled study [abstract]. Biol Psychiatry. 2007;61(8)(suppl 1):S7.
42. Keck PE, Welge JA, McElroy SL, Arnold LM, Strakowski SM. Placebo effect in randomized, controlled studies of acute bipolar mania and depression. Biol Psychiatry. 2000;47(8):748-755.
43. Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry. 2007;64(4):442-455.
44. Pope HG Jr, McElroy SL, Keck PE Jr, Hudson JI. Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry. 1991;48(1):62-68.
45. Geller B, Cooper TB, Sun K, Zimerman B, Frazier J, Williams M, Heath J. Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolesc Psychiatry. 1998;37(2):171-178.
46. Khanna S, Vieta E, Lyons B, Grossman F, Eeerdekens M, Kramer M. Risperidone in the treatment of acute mania. Br J Psychiatry. 2005;187:229-234.
47. Janicak PG, Sharma RP, Pandey G, Davis JM. Verapamil for the treatment of acute mania: a double-blind, placebo-controlled trial. Am J Psychiatry. 1998;155(7):972-973.
48. Rush AJ, Post RM, Nolen WA, Keck PE, Suppes T, Altshuler L, McElroy SL. Methodological issues in developing new acute treatments for patients with bipolar illness. Biol Psychiatry. 2000;48(6):615-624.
49. Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol. 2005;15(1):75-84.
50. Gopal S, Steffens DC, Kramer ML, Olsen MK. Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy. J Clin Psychiatry. 2005;66(8):1016- 1020.
51. Berk M, Ichim L, Brook S. Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. Int Clin Psychopharmacol. 1999;14(6):339-343.
52. Baldessarini RJ, Suppes T, Tondo L. Lithium withdrawal in bipolar disorder: implications for clinical practice and experimental therapeutics research. Am J Ther. 1996;3(7):492-496.
53. Baldessarini RJ, Tondo L, Faedda GL, Viguera AC, Baethge C, Bratti I, Hennen J. Latency, discontinuation, and re-use of lithium treatment. In: Bauer M, Grof P, Müller-Oerlinghausen B, eds. Lithium in Neuropsychiatry: The Comprehensive Guide. London, England: Taylor & Francis; 2006:465-481.
54. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Sanger T, Risser R, Zhang F, Toma V, Francis J, Tollefson GD, Breier A; Olanzipine HGGW Study Group. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2000;57(9):841-849.
55. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KN, Daniel DG, Petty F, Centorrino F, Wang R, Grundy SL, Greaney MG, Jacobs TG, David SR, Toma V; Olanzipine HGEH Study Group. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry. 1999;156(5):702-729.
56. Hirschfeld RM, Keck PE Jr, Kramer M, Karcher K, Canuso C, Eerdekens M, Grossman F. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry. 2004;161(6):1057-1065.
57. Chengappa KNR, Hennen J, Baldessarini RJ, Kupfer DJ, Yatham LN, Gershon S, Baker RW, Tohen M. Recovery and functional outcomes following olanzapine treatment for bipolar I mania. Bipolar Disord. 2005;7(1):68-76.